Article section 4 of 12.  Previous  Next

By K K Jain MD

Tiagabine hydrochloride is indicated as adjunctive therapy in the treatment of partial seizures in adults and children 12 years and older.

Off-label/investigational uses.

  • Treatment of anxiety. Open-label investigations indicate that tiagabine may be a useful addition to currently available drugs for anxiety (Schwartz and Nihalani 2006; Dunlop et al 2007).
  • Epilepsy and severe impulse control disorder.
  • Results of an open-label and double-blind discontinuation trial indicate that tiagabine may be useful for the treatment of posttraumatic stress disorder (Connor et al 2006).
  • Tiagabine suppresses nocturnal bruxism when given at bedtime (Kast 2005).
  • Management of chronic pain (Todorov et al 2005).
  • A placebo-controlled screening trial indicates that tiagabine should be considered for further study as a cocaine-dependence treatment (Winhusen et al 2005).
  • Management of painful spasticity in children (Chu and Sala 2006).
  • Posttraumatic stress disorder (Davidson et al 2007).
  • Controlled studies do not support the use of tiagabine for generalized anxiety disorder (Pollack et al 2008; Zwanzger et al 2009).
  • Essential tremor (Gironell et al 2008).

In This Article

Historical note and nomenclature
Clinical trials
Goals and duration of treatment
Precautions and use in special groups
Adverse effects
References cited